We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aptorum Group Ltd | NASDAQ:APM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1699 | 3.14% | 5.58 | 5.52 | 10.28 | 5.77 | 5.49 | 5.49 | 7,780 | 05:00:04 |
From May 2021 to May 2024
By Michael Dabaie
Aptorum Group Ltd. shares rose 30%, to $1.59, premarket after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration granted orphan drug designation to SACT-1.
The designation is for the treatment of patients with neuroblastoma. Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% to 10% of all childhood tumors, the company said.
Aptorum Group plans to file an investigational new drug application to begin a phase 1b/2a clinical trial for SACT-1 to test the drug in neuroblastoma patients in 2022.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
January 20, 2022 08:56 ET (13:56 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Aptorum Chart |
1 Month Aptorum Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
